| Literature DB >> 28420170 |
Jui-Hung Yen1, Pei-Shan Wu2, Shu-Fen Chen3, Ming-Jiuan Wu4.
Abstract
<span class="abstract_title">BACKGROUND: <span class="Chemical">Fisetin (3,7,3',4'-tetrahydroxyflavone) is a dietary flavonol and exhibits antioxidant, anti-inflammatory, and neuroprotective activities. However, high concentration of fisetin is reported to produce reactive oxygen species (ROS), induce endoplasmic reticulum (ER) stress and cause cytotoxicity in cancer cells. The aim of this study is to investigate the cytoprotective effects of low concentration of fisetin against tunicamycin (Tm)-mediated cytotoxicity in neuronal-like catecholaminergic PC12 cells.Entities:
Keywords: HO-1; SIRT1; fisetin; p38 MAPK; tunicamycin
Mesh:
Substances:
Year: 2017 PMID: 28420170 PMCID: PMC5412436 DOI: 10.3390/ijms18040852
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Effects of fisetin on tunicamycin (Tm)-induced PC12 cell death. (a) Chemical structure of fisetin; (b) Fisetin alone does not change the cell viability of PC12 cells; (c) Tm causes cell death in PC12 cells; (d) Fisetin inhibits Tm-mediated cytotoxicity in PC12 cells. Cells were treated with the indicated concentration of compound or vehicle control (0.1% dimethyl sulfoxide, DMSO) for 30 min followed by exposure to Tm for an additional 16 h at 37 °C. Cell viability was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), as described in Materials and Methods. ** p < 0.01 represents significant differences compared with vehicle control (Con, without Tm). ## p < 0.01 represents significant differences compared with the Tm-treated vehicle (veh).
Figure 2Effect of fisetin on apoptotic and autophagic marker protein expression. (a) Effect of fisetin alone on poly (ADP-ribose) polymerase-1 (PARP-1) activation and microtubule-associated protein 1 light chain 3 (LC3) conversion; (b) Effect of fisetin on Tm-activated PARP-1 activation; (c) Effect of fisetin on Tm-mediated conversion of LC3B and formation of Atg12–Atg5 conjugate. Cells were treated with the indicated reagent for 16 h and cell lysates were prepared and subjected to immunoblotting. The blots are representative from one of three independent experiments. Data obtained from immunoblots were then analyzed using ImageJ software. Data represent the mean ± SD of three independent experiments. (a) ** p < 0.01 represents significant differences compared with no fisetin control; (b,c) ** p < 0.01 represents significant differences compared with vehicle control (without Tm). # p < 0.05; ## p < 0.01 represent significant differences compared with the Tm-treated vehicle group.
Figure 3Effect of fisetin on Tm-mediated unfolded protein response (UPR). (a,c–e) Cells were treated with the indicated reagent for 6 h at 37 °C and RNA was prepared. Semi-quantitative RT-PCR and polyacrylamide electrophoresis was employed for the analysis of mRNA levels of XBP1s and XBP1u. RT-Q-PCR was used for the analysis of mRNA levels of glucose-regulated proteins 78 (GRP78), C/EBP homologous protein (CHOP) and tribbles-related protein 3 (TRB3); (b) Cells were treated with the indicated reagent for 4 h and levels of phospho-eIF2α and eIF2α were analyzed using immunoblotting; (f) Cells were treated with the indicated reagent for 8 h and GRP78 and CHOP in cell lysates were analyzed using immunoblotting. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with vehicle control (without Tm). ## p < 0.01 represents significant differences compared with the Tm-treated vehicle group.
Figure 4Effects of fisetin on intracellular ROS production. (a) PC12 cells were treated with fisetin for 16 h at 37 °C; (b) PC12 cells were treated with fisetin 30 min prior to Tm insult for 16 h at 37 °C. Intracellular ROS production was measured by 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA). Data represent the mean ± SD of three independent experiments. (a) ** p < 0.01 represents significant differences compared with no fisetin control; (b) ** p < 0.01 represents significant differences compared with control. ## p < 0.01 represents significant differences compared with the Tm-treated vehicle group.
Figure 5Fisetin induces Nrf2-targeted gene expression in the absence of Tm. (a,d–f) PC12 cells were treated with 5–20 µM Fisetin for 6 h. RNA was prepared and the mRNA levels of HO-1, GCLC, GCLM and xCT were analyzed by RT-Q-PCR and normalized to β-actin; (b,c) PC12 cells were treated with 5–20 µM fisetin for 8 or 16 h; subsequently, the cell lysates were subjected to immunoblotting for HO-1 and α-tubulin. Immunoblots were then analyzed using ImageJ software. Data represent the mean ± SD of three independent experiments. * p < 0.05, and ** p < 0.01 represents significant differences compared with vehicle control.
Figure 6Effects of fisetin on Nrf2-targeted gene expression in the presence of Tm. (a,d–f) PC12 cells were treated with fisetin 30 min prior to Tm co-treatment for 12 h at 37 °C. The mRNA levels of HO-1, GCLC, GCLM and xCT were analyzed by RT-Q-PCR and normalized to β-actin; (b) PC12 cells were treated with fisetin 30 min prior to Tm co-treatment for 16 h. Immunoblotting of HO-1 and α-tubulin were employed and the bands were quantitated using ImageJ. The data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with vehicle control (without Tm); # p < 0.01, and ## p < 0.01 represent significant differences compared with the Tm-treated vehicle group; (c) Effects of inhibition of HO-1 activity on cell viability. PC12 cells were pretreated for 30 min with Znpp, and fisetin (5–20 µM) was then added 30 min prior to Tm exposure for 16 h. MTT was used to analyze the cell viability. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with the Tm-treated respective vehicle group. ## p < 0.01 represents significant differences compared with the respective no inhibitor group.
Figure 7Involvement of MAPK signaling pathways in the cytoprotective effects of fisetin. (a,b) Effects of fisetin on MAPK activation. PC12 cells were treated with fisetin 30 min prior to Tm (1 µg/mL) treatment for 2 and 4 h at 37 °C. Cell lysates were prepared and the levels of MAPK activation were analyzed by immunoblotting; (c,d) Effects of inhibition of JNK and p38 MAPK activation on cell viability. PC12 cells were pretreated for 30 min with 5 µM JNK (SP600125) or p38 MAPK inhibitor (SB203580) and 5–20 µM fisetin was then added 30 min prior to Tm (1 µg/mL) exposure for 16 h. MTT was used to analyze the cell viability. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with the Tm-treated respective vehicle group. # p < 0.05 and ## p < 0.01 represent significant differences compared with the respective no inhibitor group.
Figure 8Effects of JNK and p38 MAPK inhibitors on UPR and oxidative stress response gene expression in response to Tm. PC12 cells were pretreated for 30 min with 5 µM JNK (SP600125) or p38 MAPK inhibitor (SB203580) and fisetin was then added 30 min prior to Tm exposure. (a,b) The mRNA levels of HO-1 and xCT were analyzed from RNA isolated after 12 h treatment of Tm; (c,d) The mRNA levels of CHOP and GRP78 were analyzed from RNA isolated after 6 h treatment of Tm. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with the Tm-treated respective vehicle group. ## p < 0.01 represents significant differences compared with the respective no inhibitor group.
Figure 9SIRT1 activity and overexpression is involved in the fisetin-mediated cytoprotective effect. (a,b) Fisetin reverses Tm-mediated SIRT1 downregulation. PC12 cells were treated with fisetin (5–20 µM) 30 min prior to Tm (1 µg/mL) treatment for 16 h at 37 °C. Cell lysates were prepared and the levels of SIRT1 and α-tubulin were analyzed by immunoblotting. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with control. ## p < 0.01 represents significant differences compared with the Tm-treated vehicle group; (c) Effects of inhibition of SIRT1 activity on cell viability. PC12 cells were pretreated for 30 min with 15 µM sirtinol and 10 or 20 µM fisetin was then added 30 min prior to Tm (1 µg/mL) exposure for 16 h. MTT was used to analyze the cell viability. Data represent the mean ± SD of three independent experiments. ** p < 0.01 represents significant differences compared with the Tm-treated respective vehicle group. ## p < 0.01 represents significant differences compared with the respective no inhibitor group.
Primary antibodies used in Western blotting.
| Antibody | Company | Catalog Number |
|---|---|---|
| α-tubulin | Sigma | T 6199 |
| β-actin | GeneTex (Hsinchu, Taiwan) | GTX629630 |
| PARP-1 | Santa Cruz | H-250 |
| LC3B | Gene Tex | GTX127375 |
| Atg12 | Gene Tex | GTX124181 |
| eIF2α | Gene Tex | GTX101241 |
| Gene Tex | GTX61039 | |
| GRP78 | BD (Franklin Lakes, NJ, USA) | 610978 |
| CHOP | Santa Cruz | sc-7351 |
| HO-1 | Enzo Life Sciences (Farmingdale, NY, USA) | SPA-895 |
| ERK | Cell Signaling (Danvers, MA, USA) | 4695 |
| Cell Signaling | 4370 | |
| p38 | Cell Signaling | 9212 |
| Cell Signaling | 9215 | |
| JNK | Cell Signaling | 9258 |
| Cell Signaling | 4668 | |
| SIRT1 | Cell Signaling | 8469 |
Primer pairs used in RT-Q-PCR.
| Gene | Primers | Amplicon (bp) |
|---|---|---|
| β-actin [ | (F) CCTCTGAACCCTAAGGCCAA | 90 |
| ATF4 [ | (F) CTTCTCCAGGTGTTCCTCGT | 163 |
| CHOP [ | (F) AAGAATCAAAAACCTTCACTACTCTTGACC | 91 |
| GCLC [ | (F) TGGCCAGCCGTACGGAGGAA | 143 |
| GCLM [ | (F) CTTTCCTTGGAGCATTTGCAGCCTT | 131 |
| GRP78 [ | (F) CAACTCACGTCCAACCCGGAGAA | 171 |
| HO-1 [ | (F) GCCTGCTAGCCTGGTTCAAG | 87 |
| TRB3 [ | (F) GGACAAGATGCGAGCCACAT | 179 |
| xCT [ | (F) GACAGTGTGTGCATCCCCTT | 110 |